Lang Yang
University of Sheffield · Sheffield University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lang Yang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:22 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT01293292 · Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of ActionSheffield Teaching Hospitals NHS Foundation Trust · completed · Osteoporosis · principal investigator
- N/ANCT00666640 · 3D Imaging of the Hip Using DXASheffield Teaching Hospitals NHS Foundation Trust · completed · Osteoporosis, Low-energy Trauma Fracture · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 14 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:22 UTC. The ranking covers the 200 most relevant of 1402 PubMed records, and a shared surname and initials can bring in a namesake. All 1402 on PubMed
- Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).J Clin Oncol · 2022435 citationsRCR 35.8
- 414 citationsRCR 25.9
- 392 citationsRCR 33.0
- 392 citationsRCR 42.0
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.N Engl J Med · 2025391 citationsRCR 108.0
- Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.J Natl Cancer Inst · 2023253 citationsRCR 23.3
- 236 citationsRCR 13.7
- 208 citationsRCR 20.3
- 139 citationsRCR 15.2
- 132 citationsRCR 11.1